NasdaqGS:ORICBiotechs
Does ORIC (ORIC) Have the Scientific Depth to Turn Enozertinib Data Into Lasting Value?
ORIC Pharmaceuticals is preparing to present new Phase 1b data for its brain-penetrant EGFR/HER2 inhibitor enozertinib (ORIC-114) in previously treated HER2 exon 20 mutant non-small cell lung cancer at the ESMO Asia Congress 2025 in Singapore, with a follow-up investor webcast on December 6, 2025.
The upcoming data disclosure is important because it centers on a genetically defined, hard-to-treat lung cancer subset where targeted treatment options remain limited, making trial design details...